CoviVac (Russia COVID-19 vaccine)

CoviVac (Russian: КовиВак) is an inactivated virus-based COVID-19 vaccine developed by the Chumakov Centre, which is an institute of the Russian Academy of Sciences. It was approved for use in Russia in February 2021, being the third COVID-19 vaccine to get approval in Russia. It obtained a permission for phase III clinical trial on 2 June 2021.

This article is about the Russian vaccine. For other uses, see Covivac (disambiguation).

CoviVac
КовиВак
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Routes of
administration		Intramuscular
ATC code
  • None
Legal status
Legal status
  • Registered in Russia on 20 February 2021
Full list of CoviVac vaccine authorizations
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.